# TauTona Group

> TauTona Group is a Redwood City operational investment fund that creates and develops medical devices, biotechnology and regenerative medicine technologies. Founded in 2010 by surgeons Geoffrey Gurtner and Michael Longaker, it combines clinical insight, shared development resources and strategic technology sales, with projects spanning laparoscopic access, hernia repair, wound healing and aesthetics.

- **Founded:** 2010
- **Headquarters:** Redwood City, United States
- **Founders:** Geoffrey C. Gurtner (Co-Founder & Managing Partner), Michael Longaker (Co-Founder & General Partner)
- **Products:** TauTona Surgical Marker, Adipose Tissue Injector (ATI), Aline HA Thread Technology, Pneumoperitoneum Assist Device (TPAD), BioBolt Surgical Stapler
- **Notable:** Surgical-marker technology sold to Novadaq in September 2013., Tissue-injector assets sold to LifeCell in January 2014., Aline dermal-filler technology assets acquired by Allergan in March 2014.

## Products & services

- **TauTona Surgical Marker** — Patented marking technology visible under fluorescence imaging and normal light; sold to Novadaq in September 2013.
- **Adipose Tissue Injector (ATI)** — Single-use fat-grafting device designed to control tissue delivery and reduce repetitive syringe work; assets sold to LifeCell in January 2014.
- **Aline HA Thread Technology** — Solid-state, resorbable hyaluronic acid thread designed for dermal filling; related assets acquired by Allergan in March 2014.
- **Pneumoperitoneum Assist Device (TPAD)** — Vacuum-assisted abdominal-wall traction device for Veress needle access; FDA 510(k) decisions dated January 12 and October 15, 2024.
- **BioBolt Surgical Stapler** — Development-stage mesh-fixation device for hernia repair, including solid meshes; March 2026 directory described final tests for 510(k) clearance.
- **TauTona Wound Dressing (TWD)** — Pullulan-collagen hydrogel scaffold designed for a moist wound environment and potential cell or small-molecule delivery; featured on a September 2024 project page.
- **Theris Medical Patch / Deferoxamine Intradermal Delivery Patch** — Investigational topical deferoxamine delivery technology licensed from Stanford research. The D-SCOUT sickle-cell leg-ulcer study was withdrawn for lack of enrollment, with zero actual participants.
- **Cell Sponge** — Pullulan and soft-collagen matrix developed as a wound dressing and potential cell-delivery scaffold; company describes laboratory and manufacturing work.

## Achievements

- Surgical-marker technology sold to Novadaq in September 2013.
- Tissue-injector assets sold to LifeCell in January 2014.
- Aline dermal-filler technology assets acquired by Allergan in March 2014.
- TPAD received FDA 510(k) substantial-equivalence decisions on January 12, 2024 (K233020), and October 15, 2024 (K242536).

## Latest updates

- **2026-03** — Flinn Foundation directory listed BioBolt Medical (TauTona Group), led by Kellen Chen, seeking $500,000 seed funding and mentorship; entry stated design freeze and hard tooling completed, with final tests for 510(k) clearance underway. These are company-reported milestones and a fundraising request, not completed financing or clearance.
- **2024-10** — FDA recorded TPAD clearance K242536 on October 15; TauTona shared a live product demonstration on LinkedIn.
- **2024-09** — Company portfolio pages featured TPAD, BioBolt and TauTona Wound Dressing; page publication dates do not establish product launch dates.

## Links

- Website: https://tautonagroup.com/
- LinkedIn: https://www.linkedin.com/company/tautona-group/
- Twitter/X: https://twitter.com/tautonagroup

---

Profile page: https://yespress.io/tautona-group
Published by YesPress — https://yespress.io
Last updated: 2026-10-27